-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback